AbbVie Inc.

New York Stock Exchange
Back to all articles
Bullish +72

AbbVie (NYSE:ABBV) Trading Up 1.4% on Analyst Upgrade

📈 AbbVie shares rose 1.4% to $256.80 after Canaccord Genuity raised its price target from $273.00 to $282.00 with a buy rating.

🔍 JPMorgan Chase upgraded the stock to 'overweight' and increased its target price from $260.00 to $280.00 on July 9th.

📊 Piper Sandler restated an 'overweight' rating with a new price objective of $298.00 in a June 23rd report.

🏦 Institutional ownership remains strong at 70.23%, with Vanguard Group increasing its stake by 1.7% to hold over $41 billion worth of shares.

📉 Trading volume declined 38% from the average daily volume of 7,082,242 shares during the recent session.

💰 AbbVie reported Q1 revenue of $15 billion, beating analyst estimates of $14.72 billion and growing 12.4% year-over-year.

📈 The company posted earnings per share of $2.65, surpassing the consensus estimate of $2.59 by $0.06.

💸 AbbVie announced a quarterly dividend of $1.73 per share with an annualized yield of 2.7% payable on August 14th.

📉 The stock trades at a PEG ratio of 0.85 and a price-to-earnings ratio of 127.64 as of the latest data.

🔬 AbbVie's product portfolio spans immunology, oncology, neuroscience, virology, and women's health therapeutic areas.

📅 Analysts project full-year EPS of $14.18 for the current fiscal year based on current consensus estimates.

🏢 Geode Capital Management LLC boosted its holdings by 10.4% in the fourth quarter to own over $10 billion worth of stock.

Bullish Signals
  • Canaccord Genuity raised its price target from $273.00 to $282.00 and maintained a buy rating, driving immediate share price appreciation.
  • JPMorgan Chase upgraded AbbVie to 'overweight' and increased its target price by $20.00 to $280.00 in late July.
  • Piper Sandler issued a new price objective of $298.00, the highest among recent analyst targets mentioned.
  • Guggenheim upgraded its price objective from $249.00 to $261.00 and assigned a 'buy' rating in early July.
  • DZ Bank upgraded its rating from 'hold' to 'strong-buy' in late April, indicating sustained institutional interest.
  • Citigroup increased its target price from $230.00 to $260.00 despite maintaining a neutral rating.
  • Vanguard Group increased its stake by 1.7% in the fourth quarter, adding over 3 million shares to its portfolio.
  • State Street Corp raised its holdings by 1.4%, increasing its position value to approximately $18.5 billion.
  • Geode Capital Management LLC significantly boosted its position by 10.4%, acquiring over 4 million additional shares.
  • Bank of America increased its stake by 1.4% in the fourth quarter, adding nearly 360,000 shares to its holdings.
  • AbbVie beat Q1 earnings estimates with $2.65 EPS versus a consensus of $2.59, demonstrating operational strength.
  • Revenue growth of 12.4% year-over-year to $15 billion indicates successful commercialization of its therapeutic portfolio.
Risk Factors
  • The dividend payout ratio is extremely high at 340.89%, suggesting the company is paying out more in dividends than its current earnings support.
Full Analysis
AbbVie Inc. (NYSE: ABBV) shares rose 1.4% to $256.80 following a price target upgrade from Canaccord Genuity, which raised its target from $273.00 to $282.00 while maintaining a buy rating. The stock reached an intraday high of $258.38 with trading volume declining 38% from the daily average. This move follows a series of positive analyst actions throughout the quarter, including upgrades and target price increases from JPMorgan Chase, Piper Sandler, Guggenheim, DZ Bank, and Citigroup. Institutional investors have significantly increased their stakes in AbbVie during the fourth quarter. Major holders include Vanguard Group, which grew its position by 1.7% to own over $41 billion worth of shares, and State Street Corp, which raised its stake by 1.4%. Geode Capital Management boosted holdings by 10.4%, while Bank of America and Norges Bank also added new positions or increased existing ones, reflecting strong institutional confidence in the biopharmaceutical giant. Financially, AbbVie reported Q1 earnings of $2.65 per share, beating consensus estimates of $2.59, with revenue reaching $15 billion against expectations of $14.72 billion. Revenue grew 12.4% year-over-year, though the company posted a negative return on equity of 576.45% and a high dividend payout ratio of 340.89%. Analysts project full-year EPS of $14.18, and the stock trades above its 50-day and 200-day moving averages with a market cap of $457.78 billion. The company focuses on complex chronic conditions through its portfolio in immunology, oncology, neuroscience, virology, and women's health. AbbVie recently announced a quarterly dividend of $1.73 per share payable on August 14th for shareholders of record on July 15th, offering an annualized yield of 2.7%. The stock currently carries a PEG ratio of 0.85 and is rated as a 'Moderate Buy' by MarketBeat with an average target price of $268.10.